Developer docs
API playgroundTry for free, no card

Search company profiles

Atalanta Therapeutics

Full company profile

uuid0000511

Namestring
Atalanta Therapeutics
Legal namestring
Atalanta Therapeutics
Websiteurl
atalantatx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Atalanta Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in Boston, Massachusetts, that develops RNA interference (RNAi) therapeutics for intractable central nervous system (CNS) diseases. The company is built around a proprietary divalent small interfering RNA (di-siRNA) platform that enables durable, selective gene silencing throughout the brain and spinal cord, including deep brain structures that conventional oligonucleotide approaches have struggled to access. Its wholly-owned pipeline comprises ATL-101 (targeting HTT for Huntington's disease), ATL-201 (targeting KCNT1 for KCNT1-related epilepsy in infants and children), ATL-301 (targeting NAV1.7 for severe chronic pain), an MSH3 program for Huntington's disease and related CNS disorders, and an undisclosed CNS disorders program; partnered programs are advanced through a strategic collaboration with Genentech, and an original strategic collaboration was also established with Biogen at founding.

The company was founded by Anastasia Khvorova, Craig Mello, and Neil Aronin of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with Series A funding exclusively from F-Prime Capital. Subsequent leadership and capital events — including a $97 million oversubscribed Series B co-led by EQT Life Sciences and Sanofi Ventures in January 2025, and a June 2025 transition that appointed Joanne Kotz as CEO and Doug Pagán as CFO & COO — brought total capital generated to $262 million and oriented the company toward Phase 1 clinical execution, with IND submissions for ATL-201 and ATL-101 planned in 2025. The organization has 51-100 employees and operates from a single Boston headquarters.

Atalanta's business model is pre-commercial: it does not yet sell pharmaceutical products and is funded entirely by equity financings and partnership economics. Future revenue is expected to flow from sales of approved RNAi therapeutics, supplemented by partnership and licensing structures, with planned Phase 1 trials in KCNT1-related epilepsy and Huntington's disease serving as the next clinical milestones on the path to commercialization.

Short descriptiontext

Atalanta Therapeutics is a clinical-stage biotechnology company developing RNAi therapies using its proprietary di-siRNA platform to treat intractable CNS diseases, including Huntington's disease, KCNT1-related epilepsy, and severe chronic pain.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNAi therapeutics, neurodegenerative disease treatments, CNS gene silencing, oligonucleotide drug development, clinical-stage biotechnology
Industry2 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Neurological Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-commercial stage company developing RNAi therapeutics for neurological diseases. Revenue will be generated from sales of approved pharmaceutical products following successful clinical trials and regulatory approval.

atalantatx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Atalanta Therapeutics is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for intractable neurological diseases. The company leverages a proprietary divalent small interfering RNA (di-siRNA) platform that enables durable, selective gene silencing throughout the brain and spinal cord, including deep brain structures. Its wholly-owned pipeline includes ATL-101 for Huntington's disease, ATL-201 for KCNT1-related epilepsy, ATL-301 for severe chronic pain, an MSH3 program, and an undisclosed CNS disorders program, with partnered programs advanced through a strategic collaboration with Genentech.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Single dose of ATL-201 produced complete seizure suppression up to four months, with therapeutic effects persisting out to six months in KCNT1 epilepsy mouse models
+2 more records
Product overview1 text field

Atalanta Therapeutics is a biotechnology company pioneering RNA interference (RNAi) therapies for intractable neurological diseases. The company's core offering is its proprietary di-siRNA (divalent small interfering RNA) platform, which enables durable, selective gene silencing throughout the brain and spinal cord. The platform supports a wholly-owned pipeline of disease-modifying programs including ATL-101 (HTT) for Huntington's disease in IND-enabling stage, ATL-201 for KCNT1-related epilepsy in pre-clinical stage with IND submission planned for 2025, ATL-301 (NAV 1.7) for pain in pre-clinical stage, an MSH3 program in discovery stage, and an undisclosed CNS disorders program. The company also advances partnered programs through a strategic collaboration with Genentech.

Product and service5 records
1ATL-101 (HTT)
CategoryInvestigational RNAi Therapy
Description

A di-siRNA therapy designed to silence the HTT gene for the treatment of Huntington's disease, a progressive neurodegenerative disease caused by expansion of the huntingtin gene. Currently in IND-enabling stage with IND submission planned for 2025.

2ATL-201
CategoryInvestigational RNAi Therapy
Description

An investigational RNAi therapy designed to reduce KCNT1 levels and normalize neuronal excitability for the treatment of KCNT1-related epilepsy, a rare severe seizure disorder affecting infants and children. Currently in pre-clinical stage with IND submission planned for 2025.

3ATL-301 (NAV 1.7)
CategoryInvestigational RNAi Therapy
Description

A di-siRNA therapy targeting Nav1.7 for the treatment of multiple indications related to severe chronic pain, currently in pre-clinical stage.

4MSH3 Program
CategoryInvestigational RNAi Therapy
Description

A discovery-stage program targeting MSH3 for Huntington's disease and related CNS disorders.

5Undisclosed CNS Disorders Program
CategoryInvestigational RNAi Therapy
Description

A discovery-stage program targeting undisclosed pathways for multiple CNS disorder indications.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Strategic collaboration with Genentech as part of Atalanta's partnered programs. Atalanta is advancing partnered programs as part of a strategic collaboration with Genentech for the development of di-siRNA therapeutics for CNS diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Strategic collaboration with Biogen established at company founding in 2018 as part of Atalanta's initial strategic collaborations alongside Genentech.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Wave Life Sciences develops stereopure oligonucleotide therapeutics for CNS diseases, with an active Huntington's disease program using allele-selective approaches. Most direct comparable: same therapeutic area (CNS), overlapping indication (HD), and parallel nucleic-acid-based modality against neurological targets.

TypeDirect peer
Description

Stoke Therapeutics uses antisense oligonucleotides (ASOs) for genetic CNS diseases, with lead programs in Dravet syndrome and autosomal dominant Alzheimer disease. Directly comparable in stage, modality class (oligonucleotide), and CNS rare-disease focus.

TypeDirect peer
Description

Arrowhead develops RNAi-based therapeutics via its TRiM platform with expanding extra-hepatic delivery capabilities, including CNS targets. Closest platform competitor in RNAi modality pursuing broad delivery beyond the liver.

TypeBroad incumbent
Description

Alnylam is the established leader in RNAi therapeutics with multiple approved products and expanding CNS programs. Larger, commercially validated incumbent whose platform progress and CNS pipeline expansions directly influence Atalanta's competitive environment.

TypeBroad incumbent
Description

Ionis is the leader in antisense oligonucleotide (ASO) therapeutics with a deep neurology pipeline including approved therapies for spinal muscular atrophy and amyotrophic lateral sclerosis. Adjacent modality (ASO vs siRNA) targeting overlapping CNS indications.

TypeDirect peer
Description

Denali Therapeutics is a clinical-stage biotech focused on neurodegeneration, with programs in Huntington's disease, ALS, and Alzheimer's. Comparable CNS-focused biotech at similar stage, though using small molecules and biologics rather than RNAi.

TypeEmerging player
Description

ProQR develops RNA-based therapies, including antisense oligonucleotides and RNA editing, for genetic diseases including CNS indications. Smaller, emerging RNA-therapeutics company with overlapping rare-disease focus.

TypeOthers
Description

Voyager Therapeutics develops gene therapies for CNS diseases including Huntington's disease and ALS. Adjacent modality (AAV-based gene therapy vs RNAi) but overlapping CNS indication space and similar stage.

TypeBroad incumbent
Description

Biogen is a large commercial-stage biotech with deep CNS/neurology franchise, including antisense oligonucleotide Spinraza. Strategic partner and founding collaborator of Atalanta, providing both validation and a potential acquirer with relevant CNS commercial infrastructure.

TypeEmerging player
Description

Sage Therapeutics develops CNS-focused therapeutics, with lead asset Zurzuvae approved for postpartum depression and pipeline in epilepsy and neurodegeneration. Comparable clinical-stage CNS biotech with similar neurology-focused strategy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Atalanta Therapeutics

Neurological Therapeuticsatalantatx.com

Atalanta Therapeutics is a clinical-stage biotechnology company developing RNAi therapies using its proprietary di-siRNA platform to treat intractable CNS diseases, including Huntington's disease, KCNT1-related epilepsy, and severe chronic pain.

What Atalanta Therapeutics does

Atalanta Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in Boston, Massachusetts, that develops RNA interference (RNAi) therapeutics for intractable central nervous system (CNS) diseases. The company is built around a proprietary divalent small interfering RNA (di-siRNA) platform that enables durable, selective gene silencing throughout the brain and spinal cord, including deep brain structures that conventional oligonucleotide approaches have struggled to access. Its wholly-owned pipeline comprises ATL-101 (targeting HTT for Huntington's disease), ATL-201 (targeting KCNT1 for KCNT1-related epilepsy in infants and children), ATL-301 (targeting NAV1.7 for severe chronic pain), an MSH3 program for Huntington's disease and related CNS disorders, and an undisclosed CNS disorders program; partnered programs are advanced through a strategic collaboration with Genentech, and an original strategic collaboration was also established with Biogen at founding.

The company was founded by Anastasia Khvorova, Craig Mello, and Neil Aronin of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with Series A funding exclusively from F-Prime Capital. Subsequent leadership and capital events — including a $97 million oversubscribed Series B co-led by EQT Life Sciences and Sanofi Ventures in January 2025, and a June 2025 transition that appointed Joanne Kotz as CEO and Doug Pagán as CFO & COO — brought total capital generated to $262 million and oriented the company toward Phase 1 clinical execution, with IND submissions for ATL-201 and ATL-101 planned in 2025. The organization has 51-100 employees and operates from a single Boston headquarters.

Atalanta's business model is pre-commercial: it does not yet sell pharmaceutical products and is funded entirely by equity financings and partnership economics. Future revenue is expected to flow from sales of approved RNAi therapeutics, supplemented by partnership and licensing structures, with planned Phase 1 trials in KCNT1-related epilepsy and Huntington's disease serving as the next clinical milestones on the path to commercialization.

Atalanta Therapeutics firmographics

Firmographics
Name
Atalanta Therapeutics
Legal name
Atalanta Therapeutics
Website
https://atalantatx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Atalanta Therapeutics is a clinical-stage biotechnology company developing RNAi therapies using its proprietary di-siRNA platform to treat intractable CNS diseases, including Huntington's disease, KCNT1-related epilepsy, and severe chronic pain.
Ownership category
akta.pro rank

Atalanta Therapeutics industry classification

Industry
Product category
Neurological Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNAi therapeutics
  • Neurodegenerative disease treatments
  • CNS gene silencing
  • Oligonucleotide drug development
  • Clinical-stage biotechnology

Where Atalanta Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Atalanta Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-commercial stage company developing RNAi therapeutics for neurological diseases. Revenue will be generated from sales of approved pharmaceutical products following successful clinical trials and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Atalanta Therapeutics product offering

Product offering

Core offering

Atalanta Therapeutics is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for intractable neurological diseases. The company leverages a proprietary divalent small interfering RNA (di-siRNA) platform that enables durable, selective gene silencing throughout the brain and spinal cord, including deep brain structures. Its wholly-owned pipeline includes ATL-101 for Huntington's disease, ATL-201 for KCNT1-related epilepsy, ATL-301 for severe chronic pain, an MSH3 program, and an undisclosed CNS disorders program, with partnered programs advanced through a strategic collaboration with Genentech.

Product overview

Atalanta Therapeutics is a biotechnology company pioneering RNA interference (RNAi) therapies for intractable neurological diseases. The company's core offering is its proprietary di-siRNA (divalent small interfering RNA) platform, which enables durable, selective gene silencing throughout the brain and spinal cord. The platform supports a wholly-owned pipeline of disease-modifying programs including ATL-101 (HTT) for Huntington's disease in IND-enabling stage, ATL-201 for KCNT1-related epilepsy in pre-clinical stage with IND submission planned for 2025, ATL-301 (NAV 1.7) for pain in pre-clinical stage, an MSH3 program in discovery stage, and an undisclosed CNS disorders program. The company also advances partnered programs through a strategic collaboration with Genentech.

Differentiator

Problem solved

Functional benefit

Products and services

  • ATL-101 (HTT) A di-siRNA therapy designed to silence the HTT gene for the treatment of Huntington's disease, a progressive neurodegenerative disease caused by expansion of the huntingtin gene. Currently in IND-enabling stage with IND submission planned for 2025.
  • ATL-201 An investigational RNAi therapy designed to reduce KCNT1 levels and normalize neuronal excitability for the treatment of KCNT1-related epilepsy, a rare severe seizure disorder affecting infants and children. Currently in pre-clinical stage with IND submission planned for 2025.
  • ATL-301 (NAV 1.7) A di-siRNA therapy targeting Nav1.7 for the treatment of multiple indications related to severe chronic pain, currently in pre-clinical stage.
  • MSH3 Program A discovery-stage program targeting MSH3 for Huntington's disease and related CNS disorders.
  • Undisclosed CNS Disorders Program A discovery-stage program targeting undisclosed pathways for multiple CNS disorder indications.

Quantifiable outcome

  • Single dose of ATL-201 produced complete seizure suppression up to four months, with therapeutic effects persisting out to six months in KCNT1 epilepsy mouse models
  • +2 more outcomes

Companies that use Atalanta Therapeutics

Customer profile

Segments4 records

Ideal customer profiles3 records

Atalanta Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Atalanta Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • GenentechcoreStrategic or Co-development Partner · 1 January 2018Strategic collaboration with Genentech as part of Atalanta's partnered programs. Atalanta is advancing partnered programs as part of a strategic collaboration with Genentech for the development of di-siRNA therapeutics for CNS diseases.
  • BiogencoreStrategic or Co-development Partner · 1 January 2018Strategic collaboration with Biogen established at company founding in 2018 as part of Atalanta's initial strategic collaborations alongside Genentech.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Atalanta Therapeutics competitors and assessment

Company assessment

Direct peers

  • Wave Life Sciences: Wave Life Sciences develops stereopure oligonucleotide therapeutics for CNS diseases, with an active Huntington's disease program using allele-selective approaches. Most direct comparable: same therapeutic area (CNS), overlapping indication (HD), and parallel nucleic-acid-based modality against neurological targets.
  • Stoke Therapeutics: Stoke Therapeutics uses antisense oligonucleotides (ASOs) for genetic CNS diseases, with lead programs in Dravet syndrome and autosomal dominant Alzheimer disease. Directly comparable in stage, modality class (oligonucleotide), and CNS rare-disease focus.
  • Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics via its TRiM platform with expanding extra-hepatic delivery capabilities, including CNS targets. Closest platform competitor in RNAi modality pursuing broad delivery beyond the liver.
  • Denali Therapeutics: Denali Therapeutics is a clinical-stage biotech focused on neurodegeneration, with programs in Huntington's disease, ALS, and Alzheimer's. Comparable CNS-focused biotech at similar stage, though using small molecules and biologics rather than RNAi.

Broad incumbents

  • Alnylam Pharmaceuticals: Alnylam is the established leader in RNAi therapeutics with multiple approved products and expanding CNS programs. Larger, commercially validated incumbent whose platform progress and CNS pipeline expansions directly influence Atalanta's competitive environment.
  • Ionis Pharmaceuticals: Ionis is the leader in antisense oligonucleotide (ASO) therapeutics with a deep neurology pipeline including approved therapies for spinal muscular atrophy and amyotrophic lateral sclerosis. Adjacent modality (ASO vs siRNA) targeting overlapping CNS indications.
  • Biogen: Biogen is a large commercial-stage biotech with deep CNS/neurology franchise, including antisense oligonucleotide Spinraza. Strategic partner and founding collaborator of Atalanta, providing both validation and a potential acquirer with relevant CNS commercial infrastructure.

Emerging players

  • ProQR Therapeutics: ProQR develops RNA-based therapies, including antisense oligonucleotides and RNA editing, for genetic diseases including CNS indications. Smaller, emerging RNA-therapeutics company with overlapping rare-disease focus.
  • Sage Therapeutics: Sage Therapeutics develops CNS-focused therapeutics, with lead asset Zurzuvae approved for postpartum depression and pipeline in epilepsy and neurodegeneration. Comparable clinical-stage CNS biotech with similar neurology-focused strategy.

Others

  • Voyager Therapeutics: Voyager Therapeutics develops gene therapies for CNS diseases including Huntington's disease and ALS. Adjacent modality (AAV-based gene therapy vs RNAi) but overlapping CNS indication space and similar stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Atalanta Therapeutics social profiles

Digital presence

Atalanta Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Atalanta Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Atalanta Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Atalanta Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atalanta Therapeutics

What does Atalanta Therapeutics do?

Atalanta Therapeutics is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for intractable neurological diseases. The company leverages a proprietary divalent small interfering RNA (di-siRNA) platform that enables durable, selective gene silencing throughout the brain and spinal cord, including deep brain structures. Its wholly-owned pipeline includes ATL-101 for Huntington's disease, ATL-201 for KCNT1-related epilepsy, ATL-301 for severe chronic pain, an MSH3 program, and an undisclosed CNS disorders program, with partnered programs advanced through a strategic collaboration with Genentech.

Is Atalanta Therapeutics a public or private company?

Atalanta Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Atalanta Therapeutics founded?

Atalanta Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is Atalanta Therapeutics based?

Atalanta Therapeutics is headquartered in Boston, United States, in the North America region.

How does Atalanta Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Atalanta Therapeutics's main competitors?

Direct peers on record are Wave Life Sciences, Stoke Therapeutics, Arrowhead Pharmaceuticals and Denali Therapeutics. Broad incumbents are Alnylam Pharmaceuticals, Ionis Pharmaceuticals and Biogen. Emerging players are ProQR Therapeutics and Sage Therapeutics. Voyager Therapeutics is listed as an others.

Does Atalanta Therapeutics have an API?

No public API is recorded for Atalanta Therapeutics.

What industry is Atalanta Therapeutics in?

Atalanta Therapeutics's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireRNAi Technology Market Size to Reach USD 13.63 Billion by 2035 | SNS InsiderAccording to SNS Insider's market research report, the global RNAi Technology Market is projected to grow from USD 3.46 billion in 2025 to USD 13.63 billion by 2035, representing a compound annual growth rate of 14.68% during the forecast period. The market growth is driven by increasing adoption of RNA interference technologies in drug discovery, precision medicine, functional genomics, and gene silencing research, with North America accounting for 42.2% market share in 2025 led by the United States. Key industry developments include Arrowhead Pharmaceuticals' global licensing agreement with Novartis for ARO-SNCA and Atalanta Therapeutics' USD 97 million Series B funding round for neurological RNAi therapies.openPR.comGlobal RNAi Technology Market: Opportunities in Targeted Therapeutics | Major Companies are Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Atalanta Therapeutics.The global RNAi technology market reached US$1.6 billion in 2022 and is projected to reach US$3.6 billion by 2031, a CAGR of 10.3%. Key players include Alnylam, Ionis, and Atalanta, with recent developments including a Phase 1 study for Alzheimer's and a collaboration for RNA delivery.MassbioMember Spotlight: Atalanta TherapeuticsAtalanta Therapeutics, a biotechnology company based in Boston, is developing RNA interference treatments for persistent central nervous system diseases. In January 2025, they completed a $97 million Series B financing to support Phase 1 clinical trials for therapies targeting KCNT1-related epilepsy and Huntington’s disease. The company aims to progress these programs toward IND submissions this year to begin trials.Pulse 2.0Atalanta Therapeutics: $97 Million (Series B) Raised For Advancing Two RNAi TherapiesAtalanta Therapeutics raised $97 million in a Series B round to advance Phase 1 trials of its RNAi therapies for KCNT1-related epilepsy and Huntington's disease. The funding, co-led by EQT Life Sciences and Sanofi Ventures, will support IND submissions this year.FinSMEsAtalanta Therapeutics Raises $75M in Series B FundingAtalanta Therapeutics raised $75M in Series B funding led by EQT Life Sciences, co-led by Sanofi Ventures. The round brings total capital to $240M, to support Phase 1 trials for KCNT1-related epilepsy and Huntington's disease. The company plans IND submissions next year.AtalantatxAtalanta Therapeutics Closes Oversubscribed $97 Million Series B Financing to Advance Two RNAi Therapies for CNS Diseases to Clinical TrialAtalanta Therapeutics closed a $97 million Series B financing to advance two RNAi therapies for KCNT1-related epilepsy and Huntington's disease. The funds will support Phase 1 clinical trials, with IND submissions planned in 2025. The financing brings total capital to $262 million.Business Wire BlogAtalanta Therapeutics Closes Oversubscribed $97 Million Series B Financing to Advance Two RNAi Therapies for CNS Diseases to Clinical TrialsAtalanta Therapeutics closed a $97 million Series B financing to advance its RNAi therapies for KCNT1-related epilepsy and Huntington's disease. The company plans IND submissions in 2025 for Phase 1 trials, with preclinical data showing durable gene silencing.PR NewswireEQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's diseaseEQT Life Sciences led a $75 million Series B round in Atalanta Therapeutics, a biotech developing RNAi therapies for epilepsy and Huntington's disease. The funding will support Phase 1 clinical trials, with IND submissions planned for next year. The round brings total capital to $240 million.Business Wire BlogAtalanta Therapeutics Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial OfficerAtalanta Therapeutics appointed Serena Hung as chief medical officer and Jeffrey Young as chief financial officer. The company plans to advance two wholly-owned programs to planned IND submissions in 2025, with a third to follow. The appointments aim to support growth in its CNS RNAi pipeline.BioSpaceAtalanta Therapeutics Appoints Alfred Sandrock to Board of DirectorsAtalanta Therapeutics appointed Alfred Sandrock, Jr. to its board of directors on March 10, 2022. Sandrock, who previously served as Biogen's executive vice president of research and development, will help inform the company's R&D strategy. He will support Atalanta's branched siRNA platform for CNS diseases.